Belinostat Data Analysis Sends TopoTarget's Shares Climbing
Shares of TopoTarget A/S gained 10 percent Tuesday following an additional analysis of data from a Phase II trial of belinostat in 89 patients with cancer of unknown primary (CUP) origin, which raises hopes that the drug, a histone deacetylase inhibitor, could have potential in solid tumors.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST